Login to Your Account



Financings NEWS
CONCLUDES $20M SERIES A
An angina drug dating back to the 1970s until its use was curtailed due to toxicity is back in development, this time aimed at rare hereditary heart disease hypertrophic cardiomyopathy (HCM) in the hands of Heart Metabolics Ltd., which relaunched as an Irish firm and disclosed Thursday a $20 million series A round.
Iconic Therapeutics Inc., a small company developing a new therapy for wet age-related macular degeneration (AMD), raised $20 million in new equity financing and appointed MPM Capital partner William Greene CEO to lead the company through mid-stage testing and beyond.
Although the amounts are shrinking, biotechs are still seeking to squeeze through the initial public offering (IPO) window. After three filings last week in the hunt for a combined raise of $174 million, Angion Biomedica Corp. registered Monday with the SEC seeking up to $35 million, including overallotments.
More Financings Headlines

Cast Your Vote

Has biotech’s bubble burst?: